Search

Your search keyword '"Mosenzon, Ofri"' showing total 21 results
Start Over Author "Mosenzon, Ofri" Publisher wiley
21 results on '"Mosenzon, Ofri"'

1. Back Cover

Author

Rossing, Peter, primary, Anker, Stefan D., additional, Filippatos, Gerasimos, additional, Pitt, Bertram, additional, Ruilope, Luis M., additional, Billings, Liana K., additional, Green, Jennifer B., additional, Koya, Daisuke, additional, Mosenzon, Ofri, additional, Pantalone, Kevin M., additional, Ahlers, Christiane, additional, Lage, Andrea, additional, Lawatscheck, Robert, additional, Scalise, Andrea, additional, and Bakris, George L., additional

Published
2023
Full Text
View/download PDF

2. The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study

Author

Rossing, Peter, primary, Anker, Stefan D., additional, Filippatos, Gerasimos, additional, Pitt, Bertram, additional, Ruilope, Luis M., additional, Billings, Liana K., additional, Green, Jennifer B., additional, Koya, Daisuke, additional, Mosenzon, Ofri, additional, Pantalone, Kevin M., additional, Ahlers, Christiane, additional, Lage, Andrea, additional, Lawatscheck, Robert, additional, Scalise, Andrea, additional, and Bakris, George L., additional

Published
2023
Full Text
View/download PDF

6. Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

Author

Wharton, Sean, primary, Calanna, Salvatore, additional, Davies, Melanie, additional, Dicker, Dror, additional, Goldman, Bryan, additional, Lingvay, Ildiko, additional, Mosenzon, Ofri, additional, Rubino, Domenica M., additional, Thomsen, Mette, additional, Wadden, Thomas A., additional, and Pedersen, Sue D., additional

Published
2021
Full Text
View/download PDF

9. The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial

Author

McEwan, Phil, primary, Morgan, Angharad R., additional, Boyce, Rebecca, additional, Bergenheim, Klas, additional, Gause‐Nilsson, Ingrid A.M., additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, Johansson, Peter A., additional, Mosenzon, Ofri, additional, Cahn, Avivit, additional, and Wilding, John P.H., additional

Published
2021
Full Text
View/download PDF

10. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58

Author

Zelniker, Thomas A., primary, Morrow, David A., additional, Mosenzon, Ofri, additional, Goodrich, Erica L., additional, Jarolim, Petr, additional, Murphy, Sabina A., additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, McGuire, Darren K., additional, Wilding, John, additional, Bode, Christoph, additional, Lewis, Basil S., additional, Gause‐Nilsson, Ingrid, additional, Langkilde, Anna Maria, additional, Fredriksson, Martin, additional, Raz, Itamar, additional, Sabatine, Marc S., additional, and Wiviott, Stephen D., additional

Published
2020
Full Text
View/download PDF

11. Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58

Author

Cahn, Avivit, primary, Wiviott, Stephen D., additional, Mosenzon, Ofri, additional, Murphy, Sabina A., additional, Goodrich, Erica L., additional, Yanuv, Ilan, additional, Rozenberg, Aliza, additional, Wilding, John P. H., additional, Leiter, Lawrence A., additional, Bhatt, Deepak L., additional, McGuire, Darren K., additional, Litwak, Leon, additional, Kooy, Adriaan, additional, Gause‐Nilsson, Ingrid A. M., additional, Fredriksson, Martin, additional, Langkilde, Anna Maria, additional, Sabatine, Marc S., additional, and Raz, Itamar, additional

Published
2020
Full Text
View/download PDF

12. Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel

Author

Consoli, Agostino, primary, Czupryniak, Leszek, additional, Duarte, Rui, additional, Jermendy, György, additional, Kautzky‐Willer, Alexandra, additional, Mathieu, Chantal, additional, Melo, Miguel, additional, Mosenzon, Ofri, additional, Nobels, Frank, additional, Papanas, Nikolaos, additional, Roman, Gabriela, additional, Schnell, Oliver, additional, Sotiropoulos, Alexis, additional, Stehouwer, Coen D. A., additional, Tack, Cees J., additional, Woo, Vincent, additional, Fadini, Gian Paolo, additional, and Raz, Itamar, additional

Published
2020
Full Text
View/download PDF

13. Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study

Author

Cahn, Avivit, primary, Raz, Itamar, additional, Bonaca, Marc, additional, Mosenzon, Ofri, additional, Murphy, Sabina A., additional, Yanuv, Ilan, additional, Rozenberg, Aliza, additional, Wilding, John P. H., additional, Bhatt, Deepak L., additional, McGuire, Darren K., additional, Gause‐Nilsson, Ingrid A. M., additional, Fredriksson, Martin, additional, Johansson, Peter A., additional, Jermendy, Gyorgy, additional, Hadjadj, Samy, additional, Langkilde, Anna Maria, additional, Sabatine, Marc S., additional, Wiviott, Stephen D., additional, and Leiter, Lawrence A., additional

Published
2020
Full Text
View/download PDF

14. Cardiovascular and renal benefits of dapagliflozin in patients with short and long‐standing type 2 diabetes: Analysis from the DECLARE‐TIMI 58 trial

Author

Bajaj, Harpreet S., primary, Raz, Itamar, additional, Mosenzon, Ofri, additional, Murphy, Sabina A., additional, Rozenberg, Aliza, additional, Yanuv, Ilan, additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, McGuire, Darren K., additional, Wilding, John P. H., additional, Gause‐Nilsson, Ingrid A. M., additional, Sabatine, Marc S., additional, Wiviott, Stephen D., additional, and Cahn, Avivit, additional

Published
2020
Full Text
View/download PDF

15. Liraglutide as add‐on to sodium‐glucose co‐transporter‐2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind, placebo‐controlled trial

Author

Blonde, Lawrence, primary, Belousova, Lidia, additional, Fainberg, Udi, additional, Garcia‐Hernandez, Pedro A., additional, Jain, Sunil M., additional, Kaltoft, Margit S., additional, Mosenzon, Ofri, additional, Nafach, Jalal, additional, Palle, Mads Sundby, additional, and Rea, Rosangela, additional

Published
2020
Full Text
View/download PDF

16. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

Author

Bain, Stephen C., primary, Mosenzon, Ofri, additional, Arechavaleta, Rosario, additional, Bogdański, Pawel, additional, Comlekci, Abdurrahman, additional, Consoli, Agostino, additional, Deerochanawong, Chaicharn, additional, Dungan, Kathleen, additional, Faingold, Maria C., additional, Farkouh, Michael E., additional, Franco, Denise R., additional, Gram, Jeppe, additional, Guja, Cristian, additional, Joshi, Pankaj, additional, Malek, Rachid, additional, Merino-Torres, Juan F., additional, Nauck, Michael A., additional, Pedersen, Sue D., additional, Sheu, Wayne H. -H., additional, Silver, Robert J., additional, Tack, Cees J., additional, Tandon, Nikhil, additional, Jeppesen, Ole K., additional, Strange, Mette, additional, Thomsen, Mette, additional, and Husain, Mansoor, additional

Published
2018
Full Text
View/download PDF

18. DECLARE‐TIMI 58: Participants’ baseline characteristics

Author

Raz, Itamar, primary, Mosenzon, Ofri, additional, Bonaca, Marc P., additional, Cahn, Avivit, additional, Kato, Eri T., additional, Silverman, Michael G., additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, McGuire, Darren K., additional, Wilding, John P. H., additional, Gause‐Nilsson, Ingrid A. M., additional, Langkilde, Anna M., additional, Johansson, Peter A., additional, Sabatine, Marc S., additional, and Wiviott, Stephen D., additional

Published
2018
Full Text
View/download PDF

21. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58.

Author

Zelniker TA, Morrow DA, Mosenzon O, Goodrich EL, Jarolim P, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding J, Bode C, Lewis BS, Gause-Nilsson I, Langkilde AM, Fredriksson M, Raz I, Sabatine MS, and Wiviott SD

Subjects
Biomarkers, Female, Glucose, Hospitalization, Humans, Male, Middle Aged, Natriuretic Peptide, Brain, Peptide Fragments, Sodium, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 epidemiology, Heart Failure drug therapy, Heart Failure epidemiology, Sodium-Glucose Transporter 2 Inhibitors, Symporters
Abstract

Aims: Dapagliflozin reduced the risk of the composite of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes mellitus in DECLARE-TIMI 58. We hypothesized that baseline N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hsTnT) levels would help identify patients who are at higher baseline risk and we describe the treatment effects of dapagliflozin in patients according to their baseline NT-proBNP and hsTnT levels., Methods and Results: This was a pre-specified biomarker study from DECLARE-TIMI 58, a randomized, double-blind, placebo-controlled CV outcomes trial of dapagliflozin. Baseline NT-proBNP and hsTnT levels were measured in the TIMI Clinical Trials Laboratory in 14 565 patients. Among the included patients, 9143 patients (62.8%) were male, 1464 (10.1%) had a history of heart failure and the mean age was 63.9 years. The median baseline NT-proBNP and hsTnT levels were 75 pg/mL [interquartile range (IQR) 35-165] and 10.2 pg/mL (IQR 6.9-15.5), respectively. Patients with higher NT-proBNP and hsTnT quartiles had higher rates of CV death/HHF (Q4 vs. Q1: NT-proBNP: 4-year Kaplan-Meier event rates 13.7% vs. 1.0%; hsTnT: 11.8% vs. 1.4%; P-trend <0.001). Dapagliflozin consistently reduced the relative risk of CV death/HHF regardless of baseline NT-proBNP (P-interaction 0.72) or hsTnT quartiles (P-interaction 0.93). Given their higher baseline risk, patients with NT-proBNP and/or hsTnT levels above the median derived larger absolute risk reductions with dapagliflozin (NT-proBNP 1.9% vs. 0%, P-interaction 0.010; hsTnT 1.8% vs. 0.1%, P-interaction 0.026)., Conclusion: Patients with type 2 diabetes mellitus and higher NT-proBNP or hsTnT levels are at increased risk of CV death and HHF. Dapagliflozin reduced the relative risk of CV death/HHF irrespective of NT-proBNP and hsTnT levels, with greater absolute risk reductions seen in patients with higher baseline biomarker levels., (© 2020 European Society of Cardiology.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results